BMJ Open· Lichtman-Mikol, S., Lang, J. M., Nagar, H., Zuhour, R., Chaung, K. V., Zaorsky, N. G., Roy, S., Mendiratta, P. M., Shoag, J. E., Janopaul-Naylor, J. R., Khani, F., Schaeffer, E. M., Kyriakopoulos, C. E., Barata, P., Brown, J. R., Garcia, J. A., Barbieri, C. E., Sun, Y., Choyke, P. L., Spratt, D. E., Jia, A. Y.·· 2026-10-06AI 评分44
STAMPEDE试验(METANOVA)方案:针对接受长期雄激素剥夺治疗的新发寡转移性前列腺癌男性的转移定向放疗多中心II期随机对照试验
Metastasis-directed radiotherapy (MDRT) for men with de novo, oligometastatic prostate cancer treated with long-term androgen deprivation therapy in the STAMPEDE trial (METANOVA): protocol for a multicentre, phase II randomised controlled trial in the USA
AI 导读
METANOVA试验是一项在美国开展的多中心II期随机对照试验,旨在评估转移定向放疗(MDRT)对接受标准治疗的新发寡转移性激素敏感前列腺癌患者的疗效及生物学影响。该试验计划入组200例患者,按1:1比例随机分配至标准治疗组或标准治疗联合MDRT组,以明确MDRT能否改善该人群的无进展生存期。
来源:BMJ Open · bmjopen.bmj.com